Read Full Study Here

Aspirin, Xarelto show no difference in preventing venous thromboembolism after TJA.

Among patients who received 5 days of rivaroxaban prophylaxis after total hip or total knee arthroplasty, extended prophylaxis with aspirin was not significantly different from rivaroxaban in the prevention of symptomatic venous thromboembolism.

After patients received once-daily oral Xarelto (rivaroxaban, Bayer Pharma) until postoperative day 5, Michael Dunbar, MD, FRCSC, PhD, and colleagues then randomly assigned 3,424 patients undergoing either THA or TKA to continue rivaroxaban or switch to aspirin for an additional 9 days after TKA or for 30 days after THA. The primary effectiveness outcome was symptomatic venous thromboembolism 90 days after randomization and the primary safety outcome was bleeding complications, including major or clinically relevant nonmajor bleeding.